Literature DB >> 32208345

Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy.

Marjo Nylund1, Tytti Vuorinen2, Laura Airas3.   

Abstract

We report here on a young woman with multiple sclerosis, who developed a condition with eosinophilia and swelling of limbs seven weeks after initiation of ocrelizumab treatment. We consider her drug reaction to be compatible with a drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome. She was treated with antihistamine and corticosteroid treatments, and recovered fully within three months of symptom onset. Ocrelizumab was not re-initiated. We are not aware of other DRESS-like cases related to ocrelizumab treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DRESS; Eosinophilia; Multiple sclerosis; Ocrelizumab

Mesh:

Substances:

Year:  2020        PMID: 32208345     DOI: 10.1016/j.msard.2020.102058

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  2 in total

Review 1.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

2.  Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe.

Authors:  Marcelo Vivolo Aun; Fernando Freua; Victor Hugo Rocha Marussi; Pedro Giavina-Bianchi
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.